OncoSec Medical (ONCSQ) Stock Price, News & Analysis

Company Overview

OncoSec Medical Incorporated was a clinical-stage biotechnology company focused on developing localized cancer immunotherapies. Its research centered on treatments designed to stimulate a patient’s immune system within tumors and potentially generate a broader systemic immune response against cancer.

The company’s principal technology platform, ImmunoPulse, used electroporation to deliver therapeutic DNA directly into tumors. Its lead investigational product, tavokinogene telseplasmid (TAVO), was designed to deliver a plasmid encoding interleukin-12, an immune-stimulating protein. OncoSec evaluated TAVO both as a standalone treatment and in combination with checkpoint inhibitors for difficult-to-treat cancers, including advanced melanoma.

OncoSec’s clinical development activities included studies conducted in the United States and other regions, with an emphasis on melanoma and additional solid tumors. The company was led during a significant portion of its clinical-development period by Daniel J. O’Connor, who served as president and chief executive officer. Its securities later traded under the symbol ONCSQ, reflecting the company’s subsequent financial and corporate restructuring history.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 62,000 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/28/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ONCSQ
• CIK: 1444307
• Web: www.oncosec.com
• Phone: (855) 662-6732
• Fax: 858-430-3832
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,970,000
• Free Float: 5,884,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -30.04